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follows. The mean fluorescent intensity (MFI) was calculated for
each protein using WinMDI software (J Trotter, Scripps Research
Institute, USA) and these values were then converted to molecules
of equivalent soluble fluorochrome (MESF) using a calibration
curve to standardize the data. The calibration curve was
constructed by operating the flow cytometer under identical condi-
tions and monitoring a mixture of beads labelled with known
amounts of fluorochrome. In this way, day-to-day variation in
fluorescence detection are controlled for, and, in addition, differ-
ences in fluorescent intensity between FITC and PE can be
normalized. Obviously we would be willing for Williamson et al
to have a copy ofthe raw data derived from these experiments and
would also refer them to our publication in the British Journal of
Haematology (1996).
The Bcl-2 and Bax protein expression presented in this paper
relate to the total population of cells, regardless of their status in
terms ofresponse to apoptotic signals, i.e. no attempt was made to
gate viable and non-viable cells. However, we agree that it is of
interest to measure Bcl-2 and Bax protein levels both before and
after exposure to drug. This indeed is the subject of our latest
publication in Leukemia & Lymphoma (1998). Briefly, our results
indicate that Bcl-2 and Bax protein levels are significantly
different in those cells that resist apoptosis when compared with
those that do not, and this difference is particularly pronounced in
terms ofBax protein expression.
In the Annexin V positivity experiments we used Annexin V as
a measure of apoptosis. It is true that Annexin V is capable of
labelling very early-stage apoptotic cells that have not yet under-
gone morphological changes. However, we would point out that in
these experiments we labelled our cells with Annexin V after incu-
bation with drug for 48 h and most of the cells that were under-
going apoptosis were in fact late-stage apoptotic cells that were
easily identified morphologically by membrane blebbing, chro-
matin condensation and general cellular shrinkage. Recent data
from our laboratory have confirmed that morphological evidence
ofapoptosis can be seen as early as 16 h after drug exposure but is
much more marked after 24 h (unpublished).
P Bentley, C Pepper and THoy
Llandough Hospital, Penlan Rd, Penarth CF 64 2XX, UK
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Insulin-like growth factor I in relation to prostate
cancer and benign prostatic hyperplasia
Sir,
We were interested to read the paper by Mantzoros et al (1997)
claiming that serum insulin-like growth factor 1 (IGF-1) levels
were elevated in prostate cancer patients and suggesting that serum
IGF-1 may represent an independent risk factor for this disease.
This is in marked contrast to our data demonstrating that serum
IGF-I and IGF-2 levels were not different in patients with prostate
cancer relative to age-matched controls (Cohen et al, 1993).
Similarly, Ho and Baxter (1997) found normal IGF-1 levels in the
sera of patients with prostate cancer. The IGFs circulate
complexed to a family of proteins known as the IGF-binding
proteins (IGFBPs), as reviewed by Daughaday et al (1986).
Apparently, unknown to these authors, IGFBPs have been shown
to interfere with radioimmunoassays (RIAs) ofthe IGFs as a result
oftheir ability to bind to the labelled IGF trace and to artifactually
elevate the readings of IGF levels, as reviewed by Rosenfeld and
Gargosky (1996). While various methods have been used to
attempt to remove the IGFBPs from the IGFs before assay, only
techniques involving acidification followed by chromatography
have been demonstrated by Bang et al (1991) to successfully
perform this separation. RIAs, such as the Nichols kit used by
Mantzoros et al (1997), use an ethanol extraction method which,
while able to remove most of the IGFBP-3 found as the 150-kDa
complex ofthe IGFs, are completely ineffectual in removing other
IGFBPs in serum including IGFBP-2 and IGFBP-4, as shown by
Frey et al (1994). In our report (Cohen et al, 1993), we have shown
a two- to threefold elevation in IGFBP-2 levels in the sera of
patients with prostate cancer as assayed by both RIA and Western
ligand blotting. We have since verified that observation on a
second cohort ofpatients and, in addition, we have demonstrated a
more moderate elevation of IGFBP-2 levels in the sera ofpatients
with benign prostatic hyperplasia. We have also recently found a
twofold elevation in the serum levels of IGFBP-4 in the sera of
prostate cancer patients. Our findings of elevated IGFBP-2 in
prostate cancer patients have also been replicated by Kanety et al
(1993) and Ho and Baxter (1997). As IGFBP-2 and IGFBP-4 are
not removed by the ethanol extraction method used by Mantzoros
et al (1997), we believe that their patients actually had normal
serum IGF-1 levels, but elevated serum IGFBP-2 and IGFBP-4
levels, leading to an artifactual elevation in the IGF-1 RIA reading.
This situation is similar to a report in the New EnglandJournal of
Medicine by Pintor et al (1989), allegedly discovering a child with
phenotypic Laron dwarfism but with normal IGF-1 levels (which
are dramatically reduced in that condition). Those authors used the
exact same Nichols IGF-1 RIA kit to measure IGF-1 levels in the
serum oftheir subject as Mantzoros et al (1997) did in their paper.
Alerted to the possibility ofan artifact by a letter to the editor from
Laron and Silbergeld (1989), the authors re-assayed their child's
serum IGF-1 with an acid-chromatography technique and discov-
ered it to be undetectable, leading them to issue a retraction oftheir
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report (Pintor et al, 1990). The editor ofthe Nev Englcand Jolunal
of Medicine at the time wrote an editorial to accompany that
retraction entitled 'An error corrected, a conclusion withdrawn,
and a lesson learned' (Relman, 1990). Unfortunately, this artifact-
prone assay remains in wide use. While many data exist in support
of a role for the IGF system in the pathogenesis of prostate cancer,
it is the autocrine-paracrine involvement of IGFs and IGFBPs that
is commonly implicated, as reviewed by Peehl et al (1996).
However, measurements of IGF-1 in two previous studies using
valid methodologies (Cohen et al, 1993; Ho and Baxter, 1997),
demonstrated normal serum levels, indicating that there is no rela-
tionship between circulating IGF-I levels and the prevalence of
prostate cancer. We would therefore like to encourage Mantzoros
et al (1997) to re-assay their patients' sera in an IGF-I assay,
which can be demonstrated to be free of IGFBP interference;
otherwise, their conclusions may not be valid.
P Cohen', D M Peehl2 acnd R Rosenfeld3x
'Children 's Hospital ofPhiladelphia, Unii'ersitr oftPennsylvaania,
Philadelphia, PA, USA; 2Department ofUrology; Stanford
Unii'ersitv Medical Center, Stanford, CA, USA; 3Department of
Pediatrics, Oregon Health Sciences University; Portland, ON, USA
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Insulin-like growth factor I in relation to prostate
cancer and benign prostatic hyperplasia - reply to the
letter from Cohen, Peehl and Rosenfeld
Sir,
We thank Dr Cohen and colleagues for their interest in our paper.
They may or may not be correct in their assertion that the labora-
tory procedure that we have used to measure insulin-like growth
factor I (IGF- 1) has reduced specificity, notwithstanding the manu-
facturers' claim of no interference. What they fail to realize,
however, is that their own study (Cohen et al, 1993) is actually
suggestive of a positive association between IGF-I and prostate
cancer. Indeed, had their study been as large as ours (51 cases and
52 controls), the difference between mean IGF-I levels of their
cases and controls would have been marginally significant
(P = 0.06). They have also made a mistake in their indication ofthe
'standard error' ofthe mean IGF-1 value, when, in reality, this must
have been the standard deviation - otherwise the standard deviation
of IGF-1 among their cases would have been much higher than
their mean value! There is a lesson here: lack of statistical signifi-
cance is frequently due to limited statistical power and should
never be the basis for a confident assertion of no association. The
other study that Cohen and colleagues refer to (Ho and Baxter,
1997) is even smaller than their own, with only seven controls.
Cohen and colleagues' claim also implies that a qualitatively
similar phenomenon would create an artificial positive association
between IGF-1 and benign prostatic hyperplasia (BPH), even
though in our study there was absolutely no relationship between
IGF- 1 and BPH after adjusting for confounding variables (Table 4
in Mantzoros et al, 1997). If they are still worried, however, they
could also look to the findings ofa new study recently published in
Science (Chan et al, 1998). Using a different assay, this study has
confirmed our findings almost to the decimal point.
CS Mantzoros"2, LB Signiorello' anid D Trichopoulos'
'Department ofEpidemiology anld Harvard Ceniterfoir cancer
Preventioni, Harvard School ofPublic Health, Bostoni, MA, USA;
2Division ofEndocrinology; Beth Israel Deaconess Medical
Ceniter, Harvard Medical School, Boston, MA, USA
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